User profiles for "author:Antoine Magnan"

Antoine Magnan

Université de Nantes, France
Verified email at univ-nantes.fr
Cited by 14019

[HTML][HTML] Effect of incorrect use of dry powder inhalers on management of patients with asthma and COPD

F Lavorini, A Magnan, JC Dubus, T Voshaar… - Respiratory …, 2008 - Elsevier
BACKGROUND: Incorrect usage of inhaler devices might have a major influence on the
clinical effectiveness of the delivered drug. This issue is poorly addressed in management …

IL-17 in severe asthma. Where do we stand?

J Chesné, F Braza, G Mahay, S Brouard… - American journal of …, 2014 - atsjournals.org
Asthma is a major chronic disease ranging from mild to severe refractory disease and is
classified into various clinical phenotypes. Severe asthma is difficult to treat and frequently …

Tissue remodelling in chronic bronchial diseases: from the epithelial to mesenchymal phenotype

M Pain, O Bermudez, P Lacoste… - European …, 2014 - Eur Respiratory Soc
Airway remodelling is a critical feature of chronic bronchial diseases, characterised by
aberrant repair of the epithelium and accumulation of fibroblasts, which contribute to …

Efficacy of mepolizumab add-on therapy on health-related quality of life and markers of asthma control in severe eosinophilic asthma (MUSCA): a randomised, double …

GL Chupp, ES Bradford, FC Albers… - The Lancet …, 2017 - thelancet.com
Background Mepolizumab, an anti-interleukin-5 monoclonal antibody approved as add-on
therapy to standard of care for patients with severe eosinophilic asthma, has been shown in …

Assessment of the Th1/Th2 Paradigm in Whole Blood in Atopy and Asthma: Increased IFN- γ –producing CD8+ T Cells in Asthma

AO Magnan, LG Mely, CA Camilla… - American journal of …, 2000 - atsjournals.org
Atopy is characterized by an immune system that is biased to T helper cell, type 2 (Th2)
activation. This condition predisposes to asthma, a disease in which a Th2 activation was …

A proof-of-concept, randomized, controlled trial of omalizumab in patients with severe, difficult-to-control, nonatopic asthma

G Garcia, A Magnan, R Chiron, C Contin-Bordes… - Chest, 2013 - Elsevier
Background While up to 50% of patients with severe asthma have no evidence of allergy,
IgE has been linked to asthma, irrespective of atopic status. Omalizumab, an anti-IgE …

[HTML][HTML] Research needs in allergy: an EAACI position paper, in collaboration with EFA

NG Papadopoulos, I Agache, S Bavbek, BM Bilo… - Clinical and translational …, 2012 - Springer
In less than half a century, allergy, originally perceived as a rare disease, has become a
major public health threat, today affecting the lives of more than 60 million people in Europe …

Onset of effect and impact on health-related quality of life, exacerbation rate, lung function, and nasal polyposis symptoms for patients with severe eosinophilic asthma …

TW Harrison, P Chanez, F Menzella… - The lancet respiratory …, 2021 - thelancet.com
Background ANDHI was done to assess the efficacy of benralizumab, including onset of
effect and impact on health-related quality of life (HRQOL), exacerbation rate, lung function …

Long-term safety and efficacy of tezepelumab in people with severe, uncontrolled asthma (DESTINATION): a randomised, placebo-controlled extension study

A Menzies-Gow, ME Wechsler… - The Lancet …, 2023 - thelancet.com
Background Tezepelumab is a human monoclonal antibody that blocks thymic stromal
lymphopoietin. The drug has been tested previously in the phase 3 NAVIGATOR …

Mesenchymal stem cells induce suppressive macrophages through phagocytosis in a mouse model of asthma

F Braza, S Dirou, V Forest, V Sauzeau, D Hassoun… - Stem Cells, 2016 - academic.oup.com
Mesenchymal stem cell (MSC) immunosuppressive functions make them attractive
candidates for anti-inflammatory therapy in allergic asthma. However, the mechanisms by …